KR102482200B1 - 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도 - Google Patents

가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도 Download PDF

Info

Publication number
KR102482200B1
KR102482200B1 KR1020187022974A KR20187022974A KR102482200B1 KR 102482200 B1 KR102482200 B1 KR 102482200B1 KR 1020187022974 A KR1020187022974 A KR 1020187022974A KR 20187022974 A KR20187022974 A KR 20187022974A KR 102482200 B1 KR102482200 B1 KR 102482200B1
Authority
KR
South Korea
Prior art keywords
unsubstituted
specifically
substituted
formula
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187022974A
Other languages
English (en)
Korean (ko)
Other versions
KR20180118623A (ko
Inventor
한스 울리히 제일호퍼
윌리엄 랄베니우스
Original Assignee
우니페르지타에트 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니페르지타에트 취리히 filed Critical 우니페르지타에트 취리히
Publication of KR20180118623A publication Critical patent/KR20180118623A/ko
Application granted granted Critical
Publication of KR102482200B1 publication Critical patent/KR102482200B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020187022974A 2016-01-27 2017-01-27 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도 Active KR102482200B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16153035.7 2016-01-27
EP16153035 2016-01-27
EP16178824.5 2016-07-11
EP16178824 2016-07-11
PCT/EP2017/051866 WO2017129801A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Publications (2)

Publication Number Publication Date
KR20180118623A KR20180118623A (ko) 2018-10-31
KR102482200B1 true KR102482200B1 (ko) 2022-12-27

Family

ID=57890845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187022974A Active KR102482200B1 (ko) 2016-01-27 2017-01-27 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도

Country Status (14)

Country Link
US (3) US10786513B2 (https=)
EP (1) EP3407886A1 (https=)
JP (2) JP7115746B2 (https=)
KR (1) KR102482200B1 (https=)
CN (1) CN108697694B (https=)
AU (1) AU2017213154B2 (https=)
BR (1) BR112018015386A2 (https=)
CA (2) CA3222584A1 (https=)
CL (1) CL2018002023A1 (https=)
IL (1) IL260775B (https=)
MX (1) MX388862B (https=)
SG (1) SG11201806393QA (https=)
UA (1) UA125463C2 (https=)
WO (1) WO2017129801A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806393QA (en) 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用
WO2019226820A1 (en) 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
KR102712565B1 (ko) 2018-09-13 2024-10-02 사니오나 에이/에스 Gabaa 수용체 리간드
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
KR20220087507A (ko) * 2019-10-23 2022-06-24 뉴로사이클 테라퓨틱스, 인크. Gabaa 수용체 조절제를 사용한 간질 병태의 치료
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514206A (ja) * 1997-09-01 2001-09-11 ロレアル 敏感肌の処理における塩素またはカリウムチャネルが付随したレセプターのアゴニストである物質の使用
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
ES2194205T3 (es) 1996-07-25 2003-11-16 Merck Sharp & Dohme Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
JPWO2005030773A1 (ja) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 新規ピラゾロピリミジン誘導体
US20050245517A1 (en) * 2004-04-29 2005-11-03 Phil Skolnick 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
KR20090047450A (ko) 2006-08-04 2009-05-12 메르츠 파마 게엠베하 운트 코. 카가아 치환된 피라졸로피리미딘, 이의 제조 방법 및 의약품으로서의 이의 용도
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
WO2009021957A2 (en) * 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
US8455476B2 (en) 2009-04-22 2013-06-04 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
JP5894161B2 (ja) 2010-08-25 2016-03-23 ネオファーム カンパニー， リミテッド 新規の複素環化合物及びこれを用いた炎症性疾患治療用組成物
US20130331394A1 (en) 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
MX362181B (es) * 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
CA2979701C (en) 2015-03-20 2023-01-03 Uwm Research Foundation, Inc. Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands
SG11201806393QA (en) 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514206A (ja) * 1997-09-01 2001-09-11 ロレアル 敏感肌の処理における塩素またはカリウムチャネルが付随したレセプターのアゴニストである物質の使用
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE LUCAS A GARCIA, BIOCHEMICAL PHARMACOLOGY, 2014.12.25., VOL:93, NR:3, PP. 370 - 379
J . S. THOMSEN ET AL: "Suppressi on of Spontaneous Scratching in Hairless Rats by Sedatives but Not by Anti pruri t ics" , SKIN PHARMACOLOGY AND PHYSIOLOGY: JOURNAL OF PHARMACOLOGICAL ANDBI OPHYSICAL

Also Published As

Publication number Publication date
CA3222584A1 (en) 2017-08-03
UA125463C2 (uk) 2022-03-16
RU2018128905A3 (https=) 2020-03-24
US20210100814A1 (en) 2021-04-08
WO2017129801A1 (en) 2017-08-03
MX388862B (es) 2025-03-20
CN108697694B (zh) 2022-12-09
JP2019507736A (ja) 2019-03-22
US20250268912A1 (en) 2025-08-28
IL260775B (en) 2021-09-30
SG11201806393QA (en) 2018-08-30
US11529359B2 (en) 2022-12-20
US10786513B2 (en) 2020-09-29
AU2017213154B2 (en) 2023-02-02
JP7115746B2 (ja) 2022-08-09
CA3012791C (en) 2024-01-23
KR20180118623A (ko) 2018-10-31
JP2022088620A (ja) 2022-06-14
BR112018015386A2 (pt) 2019-03-19
AU2017213154A1 (en) 2018-08-16
CN108697694A (zh) 2018-10-23
CA3012791A1 (en) 2017-08-03
MX2018009252A (es) 2019-01-21
RU2018128905A (ru) 2020-02-27
EP3407886A1 (en) 2018-12-05
CL2018002023A1 (es) 2019-02-01
US20190134057A1 (en) 2019-05-09
US12433898B2 (en) 2025-10-07

Similar Documents

Publication Publication Date Title
KR102482200B1 (ko) 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도
Abe et al. C1 neurons mediate a stress-induced anti-inflammatory reflex in mice
Ralvenius et al. Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
Coronel et al. Progesterone modulates pro-inflammatory cytokine expression profile after spinal cord injury: implications for neuropathic pain
Gullo et al. ERG K+ channel blockade enhances firing and epinephrine secretion in rat chromaffin cells: the missing link to LQT2‐related sudden death?
Matschke et al. A concerted action of L-and T-type Ca2+ channels regulates locus coeruleus pacemaking
Zhang et al. Nicotine evoked currents in human primary sensory neurons
de Lucas et al. GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085
JP2019513749A (ja) 衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
Meves et al. Oligodendrocytic but not neuronal Nogo restricts corticospinal axon sprouting after CNS injury
RU2781636C2 (ru) Применение модуляторов gabaa-рецептора для лечения зуда
JP2015512409A (ja) 脊髄性筋萎縮症用治療剤としての４−アミノピリジン
HK1262708A1 (en) Use of gabaa receptor modulators for treatment of itch
WO2004039409A2 (de) Zusammensetzung enthaltend aktivatoren von ik-kaliumkanälen und calcineurin-antagonisten und deren verwendung
EP3386510B1 (fr) Derives phosphores pour la prevention ou le traitement des myopathies et traumatismes musculaires
Morin Syncytial nuclear domains compartmentalize sarcolemmal dystrophin and determine response to therapy in a Duchenne muscular dystrophy mouse model
Moreno-Martinez et al. Novel FKBP12 ligand promotes functional improvement in SOD1G93A ALS mice
Kamesh Increased striatal glutamate and dopamine transmission in young VPS35 D620N knock-in mouse model of Parkinson’s disease precedes reduced neurotransmission in old age
Marra Functions of Fibroblast Growth Factor Homologous Factor 2 in Excitable Tissues
di Pisa Oral communications and posters: schedule and abstracts
Chidiac Development and characterization of pain-related sodium channel mouse model for Scn10aG1663S
박혜림 Requirement of Survival Motor Neuron protein in Fibro-adipogenic progenitors for the Maintenance of Neuromuscular Junction
Bachman The Contribution of Skeletal Muscle Stem Cells to Prepubertal Skeletal Muscle Maturation and the Implications for Pediatric Cancer Radiotherapy
Akhter The regulation of the potassium chloride co-transporter KCC2 in spinal motoneurons following peripheral nerve injury
Lin Synapse maintenance and function at the mouse neuromuscular junction: Implications in diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180809

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220127

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20220127

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220215

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220617

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220215

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220617

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220415

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20220127

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220923

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220920

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220617

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220415

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220127

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration